Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Novartis
Novartis
Roche's Xolair reduces reactions to severe food allergies in study
Reuters
Sun, 02/25/24 - 05:36 pm
Roche
Novartis
Xolair
clinical trials
food allergies
What did Big Pharma CEOs get paid in 2023?
Medical Marketing and Media
Fri, 02/23/24 - 10:22 am
Pharma CEOs
executive pay
AstraZeneca
Roche
Novartis
Novo, Novartis, BMS and J&J win judge's blessing to combine arguments in upcoming IRA hearing
Fierce Pharma
Wed, 02/21/24 - 11:25 am
Novo Nordisk
Novartis
JNJ
Bristol Myers Squibb
legal
Inflation Reduction Act
drug pricing
Novartis, zeroing in on innovative meds, launches strategic review of India outfit
Fierce Pharma
Sun, 02/18/24 - 08:36 pm
Novartis
India
FDA approves Roche, Novartis' Xolair to prevent severe outcomes from common food allergies
Fierce Pharma
Sun, 02/18/24 - 08:31 pm
Roche
Novartis
Xolair
food allergies
FDA
Novartis CEO's 2023 pay rises 21% as Roche's helmsman nets $11M in his first year
Fierce Pharma
Mon, 02/5/24 - 11:16 pm
Novartis
Roche
Pharma CEOs
executive pay
Vas Narasimhan
Thomas Schinecker
Novartis in the lead to acquire cancer drug developer MorphoSys-sources
NASDAQ.com/Reuters
Mon, 02/5/24 - 11:28 am
Novartis
M&A
MorphoSys
cancer
Amid CEO turmoil, Allarity loses rights to Novartis cancer drug over missed payments
Fierce Biotech
Fri, 02/2/24 - 11:57 am
Allarity Therapeutics
Novartis
kidney cancer
ovarian cancer
dovitinib
After Novartis' radiotherapy Pluvicto disappoints, CEO touts 'compelling case' for future growth
Fierce Pharma
Wed, 01/31/24 - 11:38 am
Novartis
earnings
Pharma CEOs
Vas Narasimhan
After GSK and Novartis handoffs, Laekna's drug fails ovarian cancer trial
Fierce Biotech
Mon, 01/29/24 - 10:27 pm
Laekna
afuresertib
clinical trials
ovarian cancer
GSK
Novartis
Incyte vets, with phase 1 within reach, raise $102M for new biotech to create better PARP, PI3K drugs
Fierce Biotech
Wed, 01/24/24 - 10:35 am
Synnovation Therapeutics
Incyte
AstraZeneca
GSK
Novartis
Pfizer
funding
cancer
PARP inhibitors
FDA requires 'boxed warning' for CAR-T cancer therapies
Reuters
Mon, 01/22/24 - 10:10 pm
CAR-T
FDA
warnings
Gilead Sciences
JNJ
Novartis
Novartis eyes $1B Lutathera acceleration with trial win in newly diagnosed neuroendocrine tumors
Fierce Pharma
Fri, 01/19/24 - 11:19 am
Novartis
Lutathera
radiopharmaceuticals
neuroendocrine tumors
Novartis Ends Phase III Peanut Allergy Trial in Another Flop for Potential Xolair Successor
BioSpace
Thu, 01/18/24 - 10:58 am
Novartis
clinical trials
peanut allergy
ligelizumab
Amgen Emerges as Potential Cytokinetics Suitor as Novartis Pulls Away: Reports
BioSpace
Fri, 01/12/24 - 09:59 am
Novartis
Cytokinetics
Amgen
M&A
Novartis drops pursuit of Cytokinetics - source
Reuters
Thu, 01/11/24 - 08:41 pm
Novartis
Cytokinetics
M&A
Novartis in advanced talks to buy Cytokinetics
Reuters
Mon, 01/8/24 - 10:29 pm
Novartis
Cytokinetics
M&A
aficamten
Novartis’ Scemblix meets primary endpoints in Phase III leukemia trial
Clinical Trials Arena
Mon, 01/8/24 - 11:41 am
Novartis
clinical trials
Scemblix
asciminib
CML
Novartis dances into JPM with $250M Calypso buyout, $185M RNAi alliance
Fierce Biotech
Mon, 01/8/24 - 11:33 am
Novartis
Calypso
M&A
RNAi
JPMHC 2024
Alphabet’s Isomorphic stacks two new deals with Lilly, Novartis worth nearly $3B ahead of JPM
Fierce Biotech
Sun, 01/7/24 - 04:19 pm
Alphabet
Isomorphic
Eli Lilly
Novartis
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »